Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient

US2020039984A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2020039984-A1
Application numberUS-201816480908-A
CountryUS
Kind codeA1
Filing dateJan 25, 2018
Priority dateJan 26, 2017
Publication dateFeb 6, 2020
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.

First claim

Opening claim text (preview).

1 . A compound represented by formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof: (In formula 1, R 1 is hydrogen, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more halogens, or C 6-20 aryl; R 2 is hydrogen, C 1-20 straight or branched alkyl, or C 1-20 straight or branched alkoxy; R 3 is hydrogen, nitro, halogen, nonsubstituted or substituted C 1-20 straight or branched alkyl, nonsubstituted or substituted C 1-20 straight or branched alkoxy, 5-10 membered heteroaryl nonsubstituted or substituted with one or more methyl groups containing one or more heteroatoms selected from the group consisting of N, O and S, which forms 6 membered cycloalkyl containing one or more heteroatoms selected from the group consisting of S and O along with R 4 , wherein, the substituted C 1-20 straight or branched alkyl and the substituted C 1-20 straight or branched alkoxy can be independently substituted with one or more substituents selected from the group consisting of halogen, C 1-3 straight or branched alkoxy, 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, and C 6-10 aryl nonsubstituted or substituted with one or more nitro groups, A 1 is hydrogen, or C 1-20 straight or branched alkyl, B 1 and B 2 are independently hydrogen, C 1-20 straight or branched alkyl, diC 1-3 straight or branched alkylamino C 1-3 straight or branched alkyl, or C 6-10 aryl, and B 1 and B 2 are linked to each other to form 5-10 membered heterocycloalkyl nonsubstituted or substituted with one or more benzyl groups containing one or more heteroatoms selected from the group consisting of N, O and S, C 1 is hydrogen, C 1-20 straight or branched alkyl, or C 1-20 straight or branched alkoxy, D 1 and D 2 are independently hydrogen, hydroxy, C 1-20 straight or branched alkyl saturated or containing one or more carbon≡carbon unsaturated bonds, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C 1-20 straight or branched alkylsulfonyl, E 1 is C 1-20 straight or branched alkyl, or C 6-10 aryl C 1-5 straight or branched alkyl, F 1 is C 1-20 straight or branched alkyl, or C 6-10 aryl, G 1 is C 1-20 straight or branched alkyl, or C 6-10 aryl; R 4 is hydrogen, hydroxy, halogen, nitro, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more ═S groups, C 1-20 straight or branched alkylsulfanyl nonsubstituted or substituted with one or more oxo (═O) groups, C 1-20 straight or branched alkylsulfonyl, 5-10 membered heterocycloalkyloxy nonsubstituted or substituted with one or more C 1-5 straight or branched alkoxycarbonyl containing one or more heteroatoms selected from the group consisting of N, O and S, nonsubstituted or substituted 5-10 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O and S, nonsubstituted or substituted C 1-20 straight or branched alkoxy, wherein, the substituted 5-10 membered heteroaryl can be substituted with one or more substituents selected from the group consisting of C 1-3 straight or branched alkyl, C 1-3 straight or branched alkoxy and C 1-3 straight or branched alkoxy C 1-3 straight or branched alkyl, wherein, the substituted C 1-20 straight or branched alkoxy can be substituted with one or more substituents selected from the group consisting of halogen, cyano, C 1-3 straight or branched alkoxy, nonsubstituted or substituted 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, and nonsubstituted or substituted C 6-10 aryl, wherein, the substituted 5-10 membered heterocycloalkyl and the substituted C 6-10 aryl can be independently substituted with one or more substituents selected from the group consisting of cyano, C 1-5 straight or branched alkoxycarbonyl, and 5-8 membered heteroaryl nonsubstituted or substituted with one or more N groups, A 3 is hydrogen, or C 1-20 straight or branched alkyl, B 3 and B 4 are independently hydrogen, C 1-20 straight or branched alkyl, diC 1-3 straight or branched alkylamino C 1-3 straight or branched alkyl, nonsubstituted or substituted C 6-10 aryl, nonsubstituted or substituted C 6-10 aryl C 1-3 straight or branched alkyl, and B 3 and B 4 are linked to each other to form 5-10 membered heterocycloalkyl nonsubstituted or substituted with one or more benzyl groups containing one or more heteroatoms selected from the group consisting of N, O and S, wherein, the substituted C 6-10 aryl can be substituted with one or more substituents selected from the group consisting of amine, halogen, C 1-5 straight or branched alkyl and C 1-5 straight or branched alkoxy, C 3 , C 4 and C 5 are independently hydrogen, amine, halogen, C 1-20 straight or branched alkyl, or C 1-20 straight or branched alkoxy, D 3 and D 4 are independently hydrogen, hydroxy, C 1-20 straight or branched alkyl saturated or containing one or more carbon≡carbon unsaturated bonds, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C 1-20 straight or branched alkylsulfonyl nonsubstituted or substituted with one or more halogens, and D 3 and D 4 are linked to each other to form 5-10 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O and S, or 5-10 membered heterocycloalkyl fused with 5 membered heteroaryl nonsubstituted or substituted with one or more methyl groups or containing one S group and one or more heteroatoms selected from the group consisting of N, O and S, E 3 is C 1-20 straight or branched alkyl, or C 6-10 aryl C 1-5 straight or branched alkyl, F 3 is C 1-20 straight or branched alkyl, or C 6-10 aryl, G 3 is C 1-20 straight or branched alkyl, or C 6-10 aryl, H 3 is C 6-10 aryl, 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, or 5-10 membered heteroaryl nonsubstituted or substituted with one or more methyl groups containing one or more heteroatoms selected from the group consisting of N, O and S, I 3 is diC 1-3 straight or branched alkylamino; R 5 is hydrogen, halogen, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more halogens, or C 1-20 straight or branched alkoxy; R 6 is hydroxy, B 5 and B 6 are independently hydrogen, C 1-20 straight or branched alkyl, C 6-10 aryl C 1-3 straight or branched alkyl, or 5-10 membered heteroaryl C 1-3 straight or branched alkyl containing one or more heteroatoms selected from the group consisting of N, O and S, D 5 and D 6 are independently hydrogen, hydroxy, C 1-20 straight or branched alkyl saturated or containing one or more carbon≡carbon unsaturated bonds, C 1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C 1-20 straight or branched alkylsulfonyl nonsubstituted or substituted with one or more halogens, E 5 is C 1-20 straight or branched alkyl saturated or containing one or more carbon≡carbon unsaturated bonds, C 1-20 straight or branched alkoxy saturated or containing one or more carbon≡carbon unsaturated bonds, C 3-10 cycloalkyloxy

Assignees

Inventors

Classifications

  • Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

  • C07D487/04Primary

    Ortho-condensed systems · CPC title

  • A61P35/00Primary

    Antineoplastic agents · CPC title

  • 1,2,4-Triazoles · CPC title

  • Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2020039984A1 cover?
Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.
Who is the assignee on this patent?
Dong Wha Pharm Co Ltd, Korea Res Inst Chemical Tech
What technology area does this patent fall under?
Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Feb 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).